The information provided on this page is intended for healthcare or affiliated professionals only.

By filling this form, you confirm that you are a healthcare or affiliated professionnal and you agree with our Privacy Policy / Cookie Policy.


Clinical

Guidelines

The European Association of Nuclear Medicine

EANM guidelines for ventilation/perfusion scintigraphy – Part 1

Bajc M, et al. Eur J Nucl Med Mol Imaging 2009; 36: 1356-1370

EANM guidelines for ventilation/perfusion scintigraphy – Part 2

Bajc M, et al. Eur J Nucl Med Mol Imaging 2009; 36: 1528-1538

Education

TECHNEGASTM Functional Lung Imaging
Ventilation SPECT/CT using TECHNEGASTM to quantify pulmonary function

Pulmonary study
V/Q SPECT using TECHNEGASTM to detect pulmonary embolism

 

Testimonials

Beyond PE clinical uses - results from clinical studies

Airflow limitation assessment in chronic airway diseases
Images were kindly provided by the Hunter New England Imaging (HNEI) at John Hunter Hospital and clinical data by the Hunter Medical Research Institute (HMRI)

Monitoring treatment response in asthmatic patients
Images and clinical data were kindly provided by the Woolcock Institute of Medical Research

Lung function evaluation before lung volume reduction surgery
Images were kindly provided by Macquarie Medical Imaging (MMI) and clinical data by Macquarie Respiratory & Sleep department at Macquarie University

Literature highlights

Edition 1 – May 2017
COPD, a new indication for using TECHNEGASTM V/Q SPECT?

View this edition

Edition 3 – October 2017
Economical value of hybrid SPECT/CT in pulmonary embolism diagnosis

View this edition

Edition 2 – August 2017
V/Q SPECT/CT as first-line modality for pulmonary embolism diagnosis

View this edition

Edition 4 – December 2018
Summary of the Lancet Commissions report on redefining airways diseases

View this edition

Latest Clinical References

CANM Guidelines for V/P SPECT in PE
Leblanc M, et al. CANM Guidelines published in November 2018

"The best widely available agent for ventilation is 99mTc-Technegas, an aerosol of carbon nanoparticles (5-200 nm) generated in a high temperature furnace (Technegas Generator, Cyclomedica). Because of the very small particle size, this agent is distributed in the lungs almost like a gas and deposited in alveoli by diffusion, where they remain stable, thus providing the best possible images for ventilation SPECT."

Lung scintigraphy in COPD
Mortensen J, et al. Semin Nucl Med 2019; 49(1): 16-21

"V/Q scintigraphy is a valuable functional imaging biomarker in relation to several aspects of COPD. Disturbances in the distribution of ventilation and perfusion, which are pertinent to the pathophysiology of COPD, are directly visualized, particularly when using inert gases or Technegas as ventilation tracers while performing the scintigraphy as SPECT."

Role of medical and molecular imaging in COPD
Myc LA, et al. Clin Transl Med 2019; 8(1): 12

"3D ventilation/perfusion SPECT imaging procedures have been used to help diagnosis. COPD patients have also been evaluated using Technegas (99mTc-labelled carbon particles). Technegas has the potential to provide valuable information for the diagnosis of COPD as it has been demonstrated to correlate positively with spirometric lung function."

SPECT Ventilation imaging in asthma
Farrow CE, et al. Semin Nucl Med 2019; 49(1): 11-15

"Technegas as a SPECT ventilation agent has a key advantage as it remains fixed after inhalation, which allows imaging of upright ventilation distribution, analogous of pulmonary function tests."

Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease
Bajc M, et al. Int J of Chron Obstruct Pulmon Dis 2017; 12: 1579-1587

"V/Q SPECT, using Technegas as the ventilation imaging agent, could diagnose and grade severity of COPD and also estimate preserved lung function in 94 patients. Moreover, V/Q SPECT appears to be a unique tool to reveal the heterogeneity of COPD caused by pulmonary comorbidities such as pulmonary embolism, left heart failure, lung tumor and pneumonia."

V/Q SPECT – Normal Values for Lobar Function and Comparison With CT Volumes
Bailey DL, et al. Semin Nucl Med 2019; 49(1): 58-61

"An advantage of using Technegas as the ventilation agent and radiolabelled macro-aggregated albumin microspheres as the perfusion agent is that the deposition pattern is fixed upon administration and thus different patient postures can be studied and the effect of gravity and position determined, even though the scans must be acquired with the subject supine using conventional gamma camera SPECT/CT systems"

Radionuclide diagnosis of pulmonary embolism
Hess S, et al. Adv Exp Med Biol 2017; 906: 49-65

"Technetium-99m (99mTc-Technegas) is widely available and relatively inexpensive while Xenon-133 is less than ideal for SPECT imaging owing to its relatively low energy and suboptimal spatial resolution."

Ventilation perfusion single photon emission computed tomography: Referral practices and diagnosis of acute pulmonary embolism in the quaternary clinical setting
Lawrence NC, et al. J Med Imaging Radiat Oncol 2018; 62(6): 777-780

"However, the standard technique for V/Q SPECT in the US involves the use of Xenon radiotracer rather than Technegas rendering direct comparison of equivocal rates less useful."

Current status of ventilation-perfusion scintigraphy for suspected pulmonary embolism
Metter DF, et al. AJR Am J Roentgenol 2017; 208(3): 489-494

"The optimal tracer for ventilation studies is Technegas, an ultra fine dispersion of 99mTc-labeled carbon. [...] Its main advantage is greater percentage deposition in the alveolar spaces and less undesirable adherence to the central airways, compared with droplet radioaerosols."

Applications of Ventilation-Perfusion Scintigraphy in Surgical Management of Chronic Obstructive Lung Disease and Cancer
Tulchinsky M, et al. Semin Nucl Med 2017; 47(6): 671-679

"The best option for ventilation evaluation is aerosolized ultrafine 99mTc-labeled impregnated carbon particles (Technegas, Cyclopharm, Australia)."